Summarized by Masters of Longevity from Longevity Technology.
BioCardia finished regulatory consultations to ready CardiAMP marketing in Japan.

Key Takeaways
- BioCardia completed regulatory consultations in Japan to prepare a filing.
- CardiAMP is an autologous mononuclear cell therapy delivered by catheter.
- Device-enabled targeted delivery was used to reach damaged heart tissue.



